Short- and long-term effects of oral vancomycin on the human intestinal microbiota

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 1, 2017, Pages 128-136

  Isaac, Sandrine ^a   Scher, Jose U ^b   Djukovic, Ana ^a   Jiménez, Nuria ^a   Littman, Dan R ^b   Abramson, Steven B ^b   Pamer, Eric G ^c   Ubeda, Carles ^a,d  

^a Centro Superior de Investigacion en Salud Publica   (Spain)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; RNA 16S; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA; FECES MICROFLORA; HIGH THROUGHPUT SEQUENCING; HUMAN; INTESTINE FLORA; KLEBSIELLA; MOUSE; NONHUMAN; SHIGELLA; ANIMAL; DRUG EFFECTS; FECES; METAGENOMICS; MICROBIOLOGY; MICROFLORA; ORAL DRUG ADMINISTRATION; PROCEDURES; TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; FECES; GASTROINTESTINAL MICROBIOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; METAGENOMICS; MICE; MICROBIOTA; MODELS, ANIMAL; TIME; VANCOMYCIN;

EID: 85014567629     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw383     Document Type: Article

References (26)

1. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-41.
2. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790-801.
3. Ivanov II, Atarashi K, Manel N et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-98.
4. Heijtz RD, Wang S, Anuar F et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011; 108: 3047-52.
5. Ubeda C, Pamer EG. Antibiotics, microbiota, and immune defense. Trends Immunol 2012; 33: 459-66.
6. Ubeda C, Taur Y, Jenq RR et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120: 4332-41.
7. Million M, Thuny F, Angelakis E et al. Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr Diabetes 2013; 3: e87.
8. Zar FA, Bakkanagari SR, Moorthi KMLSTet al. Comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
9. Johnson S, Gerding DN, Louie TJ et al. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2012; 56: 4043-5.
10. Lewis B, Buffie CG, Carter RA et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection is greater following oral vancomycin as compared with metronidazole. J Infect Dis 2015; 212: 1656-65.
11. Russell SL, Gold MJ, Hartmann M et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep 2012; 13: 440-7.
12. Candon S, Perez-Arroyo A, Marquet C et al. Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes. PLoS ONE 2015; 10: e0125448.
13. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156: 3354-9.
14. Louie TJ, Cannon K, Byrne B et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012; 55 Suppl 2: S132-42.
15. Louie TJ, Byrne B, Emery J et al. Differences of the fecal microflora with Clostridium difficile therapies. Clin Infect Dis 2015; 60 Suppl 2: S91-7.
16. Abujamel T, Cadnum JL, Jury LA et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS ONE 2013; 8: e76269.
17. Scher JU, Sczesnak A, Longman RS et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013; 2: e01202.
18. Magurran AE. Measuring Biological Diversity. African J Aquatic Sci 2004; 29: 285-6.
19. Benjamini Y, Hockberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289-300.
20. Vrieze A, Out C, Fuentes S et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014; 60: 824-31.
21. Wu H-J, Ivanov II, Darce J et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32: 815-27.
22. Zhang D, Jia H, Feng Q et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015; 21: 895-905.
23. Rashid MU, Zaura E, Buijs MJ et al. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. Clin Infect Dis 2015; 60 Suppl 2: S77-84.
24. LouieTJ, PeppeJ, WattCKet al. Tolevamer, anovelnonantibioticpolymer, compared with vancomycin in the treatment of mild to moderately severe Clostridiumdifficile-associated diarrhea. Clin Infect Dis 2006; 43: 411-20.
25. Pepin J, Valiquette L, Gagnon S et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102: 2781-8.
26. Falcone M, Russo A, Iraci F et al. Risk factors and outcomes for bloodstream infections secondary to Clostridium difficile infection. Antimicrob Agents Chemother 2015; 60: 252-7.